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Abstract The present study demonstrated that T cell factor 1
(TCF-1) protein, a component of the canonical Wnt/β-catenin
signaling pathway, can regulate the expression of runt-related
transcription factor 2 (runx2) gene and Sry-related HMG box
9 (sox9) gene, which may participate in the differentiation of
chondrosarcoma. Dedifferentiated chondrosarcoma (DDCS)
is a special variant of conventional chondrosarcoma (CCS),
associated with poor survival and high metastasis rate.
However, little is known about the mechanism of its occur-
rence; thus, no effective treatment is available except surgery.
Earlier, high expression of runx2 and low expression of sox9
were found in DDCS comparedwith CCS. UsingWestern blot
to detect clinical tissue samples (including 8 CCS samples and
8 DDCS samples) and immunohistochemistry to detect 85
different-grade chondrosarcoma specimens, a high expression
of TCF-1 in DDCS tissues was found compared with CCS
tissues. This difference in expression was related to patients’
prognosis. Results of luciferase, chromatin immunoprecipita-
tion, and gel electrophoresis mobility shift assays demonstra-
ted that TCF-1 protein could bind to the promoter of runx2
gene directly and sox9 gene indirectly. Hence, it could
regulate expression of runx2 gene positively and sox9 gene
negatively. Furthermore, in vitro and in vivo experiments
showed that TCF-1 protein was closely related to the
phenotype and aggressiveness of chondrosarcoma. In conclu-
sion, this study proved that TCF-1 participates in the dediffe-
rentiation of DDCS, which may be mediated by runx2 gene
and sox9 gene. Also, TCF-1 can be of important prognostic
value and a promising therapeutic target for DDCS patients.
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Introduction
Chondrosarcoma is a common primary bone malignancy.
Conventional chondrosarcoma (CCS) consists of three histo-
logical grades [1–3]. Also, a special kind of chondrosarcoma
exists called dedifferentiated chondrosarcoma [4]. It was first
reported by Dahlin and Beabout in 1971. It is characterized by
its special components: a low-grade chondrosarcoma (CCS)
and a high-grade malignant tumor (i.e., osteosarcoma,
undifferentiated pleomorphic sarcoma, etc.), with an abrupt
interface between them [5, 6]. This kind of tumor is associated
with a high recurrence rate, a high metastasis rate, as well as
poor prognosis. Most patients die of multiple metastases
within 2 years after disease onset [7]. Till now, little is known
about the origin of dedifferentiated chondrosarcoma and its
mechanism. Bovee et al. reported that the two different
components of dedifferentiated chondrosarcoma (DDCS)
may derive from the same precursor, but the cause of the
difference in differentiation remains unknown [8, 9]. Since
no effective therapy is available except surgery [4, 7], it is
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Canonical Wnt signaling pathway is a highly revolutiona-
rily conserved pathway that participates in a variety of
biological processes [10]. This pathway plays a key role in
the differentiation of messenchymal cells into osteocytes and
chondrocytes via runt-related transcription factor 2 (runx2)
gene [11, 12]. Canonical Wnt signals are transduced through
frizzled (FZD) family receptors and low-density lipoprotein
receptor-related protein (LRP)5/LRP6 co-receptor to the
β-catenin signaling cascade. In the presence of canonical
Wnt signaling, disheveled (DVL) is phosphorylated and
β-catenin is then released from phosphorylation for
stabilization and nuclear accumulation. Nuclear β-catenin
forms a complex with T cell factor/lymphoid enhancer factor
(TCF/LEF) family transcription factors and activates the
transcription of target genes [13]. TCF/LEF is the key factor
of canonical Wnt signaling, playing vital roles in the
formation of many kinds of tumors (i.e., gastrointestinal
tumors, lymphoid hematopoietic tumor, etc.) [14–18]. TCF/
LEF family consists of four members: TCF-1, LEF-1, TCF-3,
and TCF-4 [13]. These factors participate in a variety of dis-
eases, especially in tumor formation [14–18]. The Tcell factor
1 (TCF-1) is a molecular switch for the differentiation of bone
or cartilage by interacting with runx2 gene [11, 12]. In some
previous studies, the researchers found that runx2 and Sry-
related HMG box 9 (sox9) may participate in the dedifferen-
tiation of chondrosarcoma, but the specific mechanisms are
still unknown [19–21]. A previous study demonstrated the
difference in the sox9 and runx2 expression between DDCS
and CCS cell lines [22]. But what causes the change in sox9
and runx2 expression remains unknown.
In the present study, clinical samples were tested, in vitro
and in vivo tests were performed, and it was found that TCF-1
was related to the patients’ prognosis and the invasiveness of
DDCS. Then, the specific mechanism of the participation of
TCF-1 in the occurrence of DDCS was investigated. This
study found a more specific mechanism of DDCS formation
that had never been reported earlier. The results showed that
TCF-1 could be a marker of prognostic value. More impor-
tantly, it could be a promising therapeutic target for DDCS, for
which no effective therapy is available yet except surgery.
Results
TCF-1 expression is correlated
with the clinicopathological features of chondrosarcoma,
especially dedifferentiated chondrosarcoma. Also, it
predicts the treatment outcome
The expression level of TCF-1 is higher in DDCS than in
CCS. Western blot was performed with eight DDCS speci-
mens (dedifferentiated part confirmed by pathology) and eight
CCS specimens to investigate the expression level of TCF-1,
RUNX2, and SOX9. The results showed that the expression
level of TCF-1 and RUNX2 was higher in DDCS than in
CCS, while the expression level of SOX9 was lower in
DDCS than in CCS (Fig. 1a, b). Then, immunohistochemistry
(IHC) staining was performed in 85 different-grade
chondrosarcoma specimens to assess the expression level of
TCF-1. A total of 25 % of tumor samples were positive [23]
for TCF-1 staining. The results showed that TCF-1 expression
level was higher in DDCS than in CCS, especially in the
dedifferentiated portion of DDCS. Representative TCF-1-
positive and TCF-1-negative staining images were shown in
Fig. 1c. Also, we tested four DDCS specimens, compared the
expression level of TCF-1 between their dedifferentiated part
and their conventional chondrosarcoma part. Using Western
blot and IHC, we found that TCF-1 expression level is much
higher in dedifferentiated part than conventional part in DDCS
specimens (Fig. 1d, e). The correlation between TCF-1 ex-
pression and the clinicopathological parameters of
chondrosarcoma patients was analyzed. As summarized in
Table 1, TCF-1 expression was detected as low-grade
chondrosarcoma in 2 of 29 patients (grade I), high-grade
chondrosarcoma in 7 of 33 patients (grade II + III), and
dedifferentiated chondrosarcoma in 12 of 23 patients. The
TCF-1 expression level was significantly higher in DDCS
specimens than in CCS specimens (P = 0.001). In addition,
using Kaplan–Meier survival analysis (P < 0.05), it was found
that expression level of TCF-1 was related to patients’ survival
rate. The prognosis analysis showed that the rate of survival in
dedifferentiated chondrosarcoma patients was poor in cases
with higher TCF-1 expression level, indicating that TCF-1
Fig. 1 TCF-1 expression is correlated with clinicopathological features
of chondrosarcoma, and predicts treatment outcome. The Western blot
analysis showed that TCF-1 was highly expressed in dedifferentiated
chondrosarcoma compared with normal chondrosarcoma. Lanes 1–16
are as follows: lanes 1–4, 9–12 dedifferentiated chondrosarcoma; lanes
5–8 grade I conventional chondrosarcoma; lanes 13–16 grade II
conventional chondrosarcoma. a, b The expression of TCF-1 in a
cohort of 85 human chondrosarcoma specimens was determined by
IHC staining. c Representative images of TCF-1 IHC staining in
conventional and dedifferentiated chondrosarcoma specimens are
shown. d The expression level of TCF-1 in the conventional
chondrosarcoma part as well as dedifferentiated part is tested using
Western blot. CS1 and DDCS1 are the two parts of the same
dedifferentiated chondrosarcoma sample, so are CS2 and DDCS2, CS3
and DDCS3, and CS4 and DDCS4. e IHC also shows that in the different
part of the same dedifferentiated chondrosarcoma specimen, TCF-1
expression level differs. f The expression level of TCF-1 was in
correlation with the patients’ prognosis. Kaplan–Meier curves in
chondrosarcoma patients with or without positive TCF-1 staining.
Positive TCF-1 staining (>10 % cells stained with TCF-1) in
chondrosarcoma specimens is significantly associated with a poorer
prognosis (P < 0.050). g Follow-up of conventional chondrosarcoma
patients showed that positive expression of TCF-1 indicated poorer
relapse-free survival (P = 0.021). Data are representatives or expressed
as the mean + standard error of mean of three independent experiments.
Asterisk denotes P < 0.05
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could be a prognostic marker for dedifferentiated
chondrosarcoma (Fig. 1f). Besides, positive staining of TCF-
1 in conventional chondrosarcoma indicated poorer relapse-
free survival (Fig. 1g).
The knockdown of TCF-1 by Lentivirus-mediated shRNA
in DDCS cell line inhibited the growth of dedifferentiated
chondrosarcoma cells. The overexpression of TCF-1
by Lentivirus in CCS cell line promoted the growth
of CCS cells
Lentivirus-mediated small hairpin RNA (shRNA) was used to
knock down the expression level of TCF-1, and Lentivirus
technology was used to overexpress TCF-1 to investigate the
effect of TCF-1 on the maintenance of cell viability in
dedifferentiated as well as CCS cell lines. The results revealed
that the TCF-1 expression level was suppressed significantly
in DDCS cell line (NDCS-1) treated with Lentivirus-mediated
shRNA and upregulated in CCS cell line (SW1353) treated
with Lentivirus (Fig. 2a, b).
The cell viabilities (detected by Cell Counting Kit-8
(CCK8) assay) decreased sharply after the shTCF-1 transfec-
tion in NDCS-1, while they increased after the treatment with
Lentivirus in SW1353 cells (Fig. 2c, d). The Transwell assay
showed that the overexpression of TCF-1 could promote the
invasion ability of SW1353 cells while the inhibition of TCF-
1 expression could repress NDCS-1 cell invasion ability
(Fig. 2e, f). The colony formation assay showed that owing
to the inhibition of TCF-1, the capacities of colony formation
of NDCS-1 cells significantly decreased while those of
SW1353 cells increased (Fig. 2g, h). Therefore, the repression
of TCF-1 inhibited the growth of dedifferentiated
chondrosarcoma cells, while the overexpression of TCF-1
increased the growth of CCS cells.
Results of luciferase, chromatin immunoprecipitation,
and electrophoretic mobility shift assays showed that
TCF-1 could regulate runx2 directly and sox9 indirectly
To assess whether TCF-1 can regulate runx2 and sox9
expression at the transcriptional level, luciferase reporter
assays were performed to verify the TCF-1 effect on runx2
and sox9 promoters. TCF-1 overexpression in HeLa cell lines
significantly upregulated the runx2 promoter activity and
downregulated the sox9 promoter activity (Fig. 3a).
The chromatin immunoprecipitation (ChIP) assay was
performed to confirm whether TCF-1 could bind directly to
runx2 and sox9 gene promoters using an anti-TCF-1 antibody.
The polymerase chain reaction (PCR) analysis of the TCF-1-
immunoprecipitates showed negative results for sox9 gene but
positive results for runx2 gene in NDCS-1 cell lines (Fig. 3b).
Thus, it was hypothesized that TCF-1 might regulate sox9
indirectly but it can bind directly to the runx2 gene promoter.
To further determine whether the binding site is the runx2
promoter, electrophoretic mobility shift assay (EMSA) was
performed using an oligonucleotide probe. Nuclear extracts
were super-shifted by the anti-TCF-1 antibodies, indicating
that TCF-1 binds to the runx2 promoter. On the contrary, in
sox9 gene, the result was negative. To further confirm whether
TCF-1 binds to the runx2 promoter specifically, another
EMSA test was performed using both TCF-1 wild-type probe
and mutated probe. Positive results were obtained using the
TCF-1 wild-type probe than the mutated probe (Fig. 3c, d).
These findings indicated that TCF-1 activated runx2 gene
expression by directly binding to the runx2 promoter, while
it could regulate sox9 gene expression indirectly.
The inhibition of TCF-1 by shRNA in NDCS-1 cells
inhibited cell division, while the overexpression of TCF-1
by Lentivirus in SW1353 cells promoted cell division.
The inhibition of TCF-1 expression in NDCS-1 cells also
promoted early apoptosis as well as necrosis
Here, propidium iodide (PI) staining and flow cytometry were
used to determine whether TCF-1 could influence cell
division in DDCS as well as CCS cells. In NDCS-1 cell line,
the shTCF-1 altered the distribution of dedifferentiated
chondrosarcoma cells in different stages of the cell cycle and
its progression. The results showed that on treatment with
shTCF-1 in NDCS-1 cells, the cells in the G0/G1 phase
increased while the cells in the G2/M phase decreased,
compared with the control group. In SW1353 cells, the
overexpression of TCF-1 could decrease the percentage of
cells in the G0/G1 phase and increase the percentage of cells
in the G2/M phase, compared with the control group
Table 1 The relationship between TCF-1 expression and clinicopath-
ological variables of chondrosarcoma
Clinopathological variables No. of cases TCF-1 expression P value
Positive Negative
Sex 0.953
Male 45 11 34
Female 40 10 30
Age 0.961
≥40 years 53 13 40
<40 years 32 8 24
Anatomical location 0.758
Limb bone 34 9 25
Axial bone 51 12 39
Grade of tumor 0.001
Low (grade I) 29 2 27
High (grade II + III) 33 7 26
Dedifferentiated 23 12 11
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(Fig. 4a, b). In the NDCS-1 cell line, the downregulation of
TCF-1 protein promoted early apoptosis as well as necrosis
(Fig. 4c). These results showed that the inhibition of TCF-1 by
shRNA in NDCS-1 cells inhibited cell division, while the
Fig. 2 Effects of overexpressed TCF-1 on SW1353 cell lines and
downregulated TCF-1 on NDCS-1 cell lines. Expression of protein
levels of TCF-1 in NDCS-1 and SW1353 cells were significantly
changed at 48 h after shTCF-1 or Lentivirus transfection. The shTCF-1
and Lentivirus transfection efficiency were measured by Western blot (a,
b). The cell viability of NDCS-1 (c) and SW1353 (d) was determined
using the CCK8 assay. The overexpression of TCF-1 could promote
SW1353 cell proliferation, while the downregulation of TCF-1 could
decrease NDCS-1 cell proliferation. The invasiveness ability of NDCS-
1 (e) and SW1353 (f) cells was examined using the Transwell assay.
Images of invasion in NDCS-1 (e) and SW1353 (f) cells are
represented by overexpressed or downregulated TCF-1. The
overexpression of TCF-1 could promote the invasive ability of SW1353
cells, while the downregulation of TCF-1 could decrease the invasive
ability of NDCS-1 cells. The average number of cells per field was
calculated. A significant difference in the number of colonies was
expressed between downregulated TCF-1 NDCS-1 (g) or overexpressed
TCF-1 SW1353 cells (h) with the vector control NDCS-1 or SW1353
cells. Data are representatives or expressed as the mean + standard error
of mean of three independent experiments. Asterisk denotes P < 0.05
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overexpression of TCF-1 by Lentivirus in SW1353 cells
promoted cell division.
The downregulation of TCF-1 in NDCS-1 cell line could
alter the expression level of sox9 and runx2,
and the phenotype of NDCS-1 cells as well as SW1353 cells
changed after a change in the TCF-1 expression level
To confirm whether a change in the TCF-1 expression level
could change the expression level of sox9 and runx2
subsequently, Western blot analysis and reverse-transcription
(RT)-PCR test were performed. The results showed that in
NDCS-1 cells, the downregulation of TCF-1 decreased the
expression level of runx2 but increased the expression level
of sox9 (Fig. 4d). While in SW1353 cells, the overexpression
of TCF-1 increased the expression level of runx2 but de-
creased the expression level of sox9 (Fig. 4e). These results
indicated that sox9 and runx2 were regulated by TCF-1 in
dedifferentiated chondrosarcoma. To further confirm whether
the change in phenotype in dedifferentiated chondrosarcoma
Fig. 3 Luciferase, ChIP, and EMSA results showing the specific
mechanism that TCF-1 regulates the expression level of runx2 and
sox9. Luciferase assay of the runx2 promoter and sox9 promoter
activity 48 h after co-transfection of Renilla luciferase and the reporter
plasmid pGL/RUNX2 or pGL/SOX9 in Hela cell lines transduced with
TCF-1 expression plasmid (a). The ChIP assay: protein–DNA complexes
from NDCS-1 cells were incubated with TCF-1 antibody. The binding of
runx2 DNA was detected by PCR amplification using runx2-specific
primers. Immunoglobulin G (IgG) antibody and glyceraldehyde-3-
phosphate dehydrogenase primers were used in this assay as negative
controls. Lanes 1–6 are as follows: 1 DNA marker (MD101), 2 input, 3
IgG, 4 anti-TCF-1, 5 anti-RNA polymerase II, and 6 GAPDH promoter-
specific DNA (b). The super gel shift assay showed the binding of TCF-1
with RUNX2 DNA in nuclear extracts prepared from chondrosarcoma
cell lines. For experimental controls, the labeled RUNX2 probes were
incubated alone, with nuclear extracts, in combination with nuclear
extracts and unlabeled probe, or in combination with nuclear extracts
and IgG antibody (c, d). Asterisk denotes P < 0.05; two asterisks denote
P < 0.01
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Fig. 4 Effects of TCF-1 on the cell cycle, apoptosis, expression level of
SOX9 and RUNX2, as well as cell phenotype in NDCS-1 and SW1353
cell lines. Cells were subjected to PI staining and FACS analysis to
determine cell cycle profile in down-regulated TCF-1 in NDCS-1 (a) or
overexpressed TCF-1 in SW1353 cells (b). Apoptotic index was
determined by the percentage of cells positive for both PI and Annexin
V in downregulated TCF-1 in NDCS-1 cells (c). Western blot and real-
time PCR were performed to evaluate the relative expression of TCF-1,
runx2, and sox9 between wild-type and TCF-1 downregulated NDCS-1
cells (d) as well as in wild-type and TCF-1 up-regulated SW1353 cells
(e). Between wild-type NDCS-1, SW1353, TCF-1 downregulated
NDCS-1, and TCF-1 overexpressed SW1353 cells, Western blot was
performed using col1a1 antibody (Santa Cruz sc-59772) and col2a1
antibody (Santa Cruz sc-52658) to observe the change in the cell
phenotype (f). Glyceraldehyde-3-phosphate dehydrogenase was used as
an internal control for protein equal loading. Data are representatives or
expressed as the mean + standard error of mean of three independent
experiments. Asterisk denotes P < 0.05
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was caused by TCF-1, Western blot was performed using
col1a1 and col2a1 antibodies. It was observed that in DDCS
as well as CCS cell lines, a change in the TCF-1 expression
level caused a change in the phenotype of cells (Fig. 4f).
The downregulation of TCF-1 inhibited the growth
of dedifferentiated chondrosarcoma in vivo
To confirm the aforementioned in vitro findings, in vivo
xenograft models were established. The mouse group injected
with NDCS-1, in which TCF-1 was downregulated, had a
lower proliferation rate and developed a smaller tumor
compared with the negative control group (Fig. 5). The data
suggested that the downregulation of TCF-1 inhibits the
growth of dedifferentiated chondrosarcoma cells in vivo.
Methods
Patients, tissue samples, and follow-up
Eight dedifferentiated chondrosarcoma tissue samples, four
grade I CCS tissue samples, and four grade II CCS tissue
samples were collected under the protocols approved by the
Ethics Committee of Peking University People’s Hospital.
Informed consents (written in the light of the ethical guide-
lines) were obtained from all the patients. A total of 85
formalin-fixed and paraffin-embedded tissue specimens of
histopathologically diagnosed chondrosarcoma (including
different grades of CCS and DDCS) were obtained from the
Department of Pathology and the Musculoskeletal Tumor
Center, Peking University People’s Hospital (Beijing,
China). The clinical features of these specimens are shown
in Table 1. The tissue samples were collected after operation,
sectioned (4 μm thickness), and preserved at room
temperature until required for the experiment. Clinical and
histopathological information was recorded through a
retrospective review of the patient records.
IHC assays for TCF-1
The tissue sections were deparaffinized, and the antigen was
retrieved using an antigen retrieval solution. The paraffinized
sections were then incubated with a rabbit polyclonal
anti-TCF-1 antibody (CST-2203s, dilution, 1:100) overnight
at 4 °C, followed by staining with a biotinylated secondary
antibody. Known positive controls were included in each
experiment, and negative controls were obtained by staining
with a nonimmune mouse serum (dilution, 1:100) in
phosphate-buffered saline (PBS) instead of the primary
antibody. When more than 10 % of tumor cells stained
positive for TCF-1, the tumor was considered positive for
TCF-1 staining. Immunostaining was evaluated by two
independent pathologists who were blinded to the clinical
characteristics and outcomes.
Western blot
Whole-cell and tissue lysates were made using cell lysis buffer
(CST) supplemented with proteinase inhibitors. Protein
concentrations were determined using the bicinchoninic acid
protein assay. Equal amounts of proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to a polyvinylidene fluoride membrane
(Amersham Bioscience). After blocking with 5 % BSA, the
primary antibody, human TCF-1 (CST-2203), human Runx2
(CST-12556), human Sox9 (CST-14366), and β-actin (CST-
4967) were incubated overnight at 4 °C (dilution 1:1000,
1:1000, 1:1000, and 1:1000, respectively). Then, the appro-
priate secondary antibody was incubated for 1 h, and the blot
was visualized using a Super Signal West Pico Trial Kit
(Thermo). The band signals were quantified using ImageJ
(Wayne Rasband).
Cell culture, Lentivirus-mediated shRNA,
and transfection
The cell lines used in this research included human DDCS cell
line NDCS-1 and human CCS cell line SW1353. The NDCS-
1 cell line was kindly provided by Dr Akira Ogose (Niigata
Fig. 5 Tumorigenicity ability of wild-type and TCF-1 downregulated
NDCS-1 cells. Tumorigenicity was evaluated by nude mice assay. Mice
were injected in the right flank subcutaneously with 2 × 106 cells. After
1 month of cell injection, the volume of tumor was calculated (left panel)
according to the formula: 0.5 × length × width2. Data are representatives
or expressed as the mean + standard error of mean of three independent
experiments. Asterisk denotes P < 0.05
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University Graduate School of Medical and Dental Sciences,
Japan), while the SW1353 cell line was purchased from
ATCC. NDCS-1 and SW1353 were grown in 1640 (Gibco)
medium and L-15 (Gibco) medium, respectively,
supplemented with 10 % fetal bovine serum (Gibco) and
1 % antibiotics. The cultures were maintained at 37 °C in
5 % atmospheric CO2.
Lentivirus particle generation and Lentivirus-mediated
shRNA gene overexpression and knockdown
Full-length TCF-1 cDNA and TCF-1 shRNA sequence was
subcloned into lentiviral vector pLVTHM. Lentivirus was
produced following previously established procedures.
Briefly, 293T cells were plated 3 days before transfection.
TCF-1 shRNA pLVTHM plasmid was mixed with envelop
plasmid (pMD2G) and packaging plasmid (psPAX2) in
desired ratio and transfected 293Tcells by calcium phosphate.
Fresh media were changed 14–16 h post-transfection and
supernatant containing Lentivirus were collected 12 h later.
Supernatants can be harvested three times every 12 h. Titers
of virus were determined using 293T. Three targeting
sequences for TCF-1 were used to generate TCF-1 overex-
pression and shRNA Lentivirus (#1GAGACGCTAGTGGA
GGAGTGCAATA; #2 CGGTCCCTTAGTGACAGTGT
CTACA; #3 GCGTGTCTACAACTGGTTTGC) and tested
for TCF-1 overexpression and knockdown. The #2 sequence
had the highest TCF-1 knockdown efficiency and was used to
generate stable TCF-1 knockdown NDCS1 cell lines in this
study. Efficiency of TCF-1 overexpression and knockdown
was confirmed by qPCR and Western blot. The sequence of
control shRNA is as follows: 5′-TTCTCCGAACGTGT
CAGCTTT-3′.
Dual-luciferase reporter assay
For the dual-luciferase reporter assay, 1 × 105 cells per well in
24-well plates were seeded the day before transfection. The
cells were transfected with 1.0 μg of pGL3-RUNX2-
promoter-luciferase or pGL3-SOX9-promoter-luciferase
together with 0.2 μg of PRL-TK or 0.4 μg of RhoE-promot-
er-luciferase. The cells were harvested for 48 h and then
detected using the dual-luciferase reporter assay system kit
(Promega, WI, USA). The luciferase activity was measured
using the Synergy2 instrument (BioTek, VT, USA) equipped
with the Gen5 software. The firefly luciferase expression was
normalized to Renilla luciferase and reported as relative
luciferase activity.
Chromatin immunoprecipitation assay
The ChIP assay was performed using a EZ ChIP Kit from
M i l l i p o r e . P r o t e i n –DNA c o m p l e x e s w e r e
immunoprecipitated with TCF-1 antibody, with rabbit serum
as a control. Then, the samples were subjected to PCR analy-
sis with the following primers: for RUNX2, promoter 5′-
CAGCCACCGAGACCAACA-3 ′ and 5 ′ -CAGT
ATGCCTGGAGTACATAGACTT-3′, and for SOX9, pro-
moter 5′-GCTCAAGGTCGATGTGGCG-3′ and 5′-GGTG
CGGCTGGTCAGGATT-3′. Sonicated DNA fragment prior
to immunoprecipitation was used as an input control, and 5′-
TCTCCACACCTATGGTGCAA-3 ′ and 5 ′ -TTGC
CGTGAGTGGAGTCATA-3′ served as the negative control.
Electrophoretic mobility shift assay
Nuclear extracts from NDCS-1 cells were prepared using a
nuclear extraction kit (Thermo Fisher, CA, USA) according
to the manufacturer’s protocol. Oligonucleotides were
synthesized by Life Technologies (Shanghai, China) and
biotinylated using a Biotin 3′-end DNA labeling kit (Thermo
Fisher) according to the manufacturer’s protocol. The
sequences used were 5′-TTGTTTTGTTTCTTTGCTTT
TCACATGT-3′ and its complementary sequence. The mutant
sequences were 5′-TTGTTTTGTTTGGGCCCTTTTCACAT
GT-3′. Binding reactions were performed using a LightShift
Chemiluminescent EMSA kit (Thermo Fisher) according to
the manufacturer’s protocol. Briefly, nuclear protein samples
(10 μg) were incubated with Biotin-labeled TCF-1
oligonucleotide for 20 min at room temperature in reaction
buffer [2 mM MgCl2, 0.1 mM ZnSO4, 7.5 % glycerol,
10 ng/μL of poly(dAdT) (Sigma), and 1 μg of bovine serum
albumin] and probe alone as a nonspecific competitor. The
analyzed DNA–protein complexes were electrophoresed in
4 % polyacrylamide gels containing 0.5× TBE buffer, and
then transferred to a positively charged nylon membrane
(Bio-Rad, CA, USA) using a semi-dry transfer blotter. The
image was visualized and scanned using a SuperSignal West
Pico chemiluminescent substrate kit (Pierce, IL, USA).
In vitro cell invasiveness tests
Cell proliferation assay
The cell proliferation assay was performed using a Cell
Counting Kit-8 (Dojindo, Japan), a redox assay similar to
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay according to the manufacturer’s protocol.
Apoptosis analysis
After washing the cells three times with ice-cold PBS, they
were resuspended in binding buffer, stained with Annexin
V-FITC (BD Biosciences) and PI (Sigma-Aldrich), and
analyzed by flow cytometry (BD Biosciences).
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Cell cycle assay
The cells were seeded 16 h before analysis (20 % of
confluence), collected, and stained with 200 μg/mL of PI,
0.1 % sodium azide, 0.1 % Triton X-100, and 10 μg/mL of
RNAses for 2–4 h. Single cells were analyzed for subG1, S,
and G2 peaks using fluorescence-activated cell sorting array
(BD Bioscience). The analysis was performed using the
FlowJo software.
Invasion assay
The migration of the cells was measured by counting the
number of cells that migrated through Transwell inserts with
3-μm pores, as described previously. The cells were
trypsinized, and 200 μL of cell suspension (1 × 106 cells/
mL) from each treatment was added in triplicate wells. After
24-h incubation, the cells that had migrated through the filter
into the lower wells were quantitated using the gentian violet
assay and expressed as the total number of cells in the lower
wells.
Colony formation assay
A total of 500 cancer cells per well were seeded in a six-well
plate. After culture for 2–3 weeks, the cell culture was
terminated and the plate was washed with PBS twice. The
cells were fixed with 4 % paraformaldehyde for 15 min.
Then, the cells were incubated with Trypan blue for 10 min,
and the staining solution was washed.
Western blot
Standard Western blot was performed to measure the
expression level of TCF-1, Runx2, and Sox9 proteins as
described previously.
RT-qPCR assay
Total RNA was extracted using Trizol reagent (Invitrogen,
CA, USA), and the reverse-transcription reactions were per-
formed using an M-MLV Reverse Transcriptase kit
(Invitrogen). Real-time PCR was performed using a standard
SYBR Green PCR kit (Toyobo, Osaka, Japan). The primers
used in RT-PCR were as follows: TCF-1 forward, 5′-CCCA
CCAAGCAGGTCTTCAC-3′; TCF-1 reverse, 5′-AAGG
TCTCGATGACGCTGTG-3′; RUNX2 forward, 5′-ACAG
TGACACCATGTCAGCA-3′; RUNX2 reverse, 5′-TCGG
CGATGATCTCCACCAT-3′; SOX9 forward, 5′-GGAC
CACCCGGATTACAAGT-3′; and SOX9 reverse, 5′-AAGA
TGGCGTTGGGGGAGAT-3′. mRNA levels were calculated
as the fold change of control.
Xenograft tumorigenicity assays
Nude BALB/c mice (6 weeks old, female, 20 to 30 g body
weight) were purchased from Shanghai SLAC Laboratory
animal Co. Ltd. (Shanghai, China) and maintained under
pathogen-free conditions. All animal experiments proceeded
according to the standards of Institutional Animal Care and
Use Committee and performed according to an established
protocol approved by the Ethics Committee of Peking
University People’s Hospital. The cells (2 × 106) were
introduced by subcutaneous implantation in PBS into
6-week-old immunodeficient nude mice. The mice were
sacrificed 30 days after tumor implantation. The volumes of
tumors were measured every 5 days and calculated as
V = a × b2 × π/6.
Statistical analysis
All statistical analyses were performed using the SPSS19.0
software package (SPSS Inc., Chicago, IL, USA). The
relationship between patient survival and indicated protein
levels was assessed using the Kaplan–Meier analysis. The
correlation between protein levels and clinicopathological
tumor grading was analyzed using standard χ2 test.
Student’s t test was used to specify the differences with a
P < 0.05.
Discussion
Dedifferentiated chondrosarcoma is a special variant of
chondrosarcoma, most commonly seen in cases with local
recurrence. It is a kind of highly malignant tumor with a high
local recurrence rate and distal metastasis rate. Till now, no
effective therapy is available for this tumor except surgery [7].
With regard to the origin of the two different cell components
in DDCS, Bridge et al. showed that they arise from the same
precursor. However, the reason for the difference in
differentiation is still unknown [24]. Most previous researches
about DDCS were case reports rather than researches on
mechanism. This study focused on the pathway andmolecules
that participate in DDCS occurrence, which is vital to explore
a novel therapy for this tumor.
sox9 and runx2 are two key factors that participate in bone
and cartilage formation [11]. sox9 participates in the matura-
tion of chondrocytes. It can regulate the expression of col2a1
gene, which is a specific marker of chondrocytes [25–30]. It
also participates in the occurrence of chondrosarcoma [19,
20]. runx2 gene is a key point that regulates the differentiation
of osteocytes from mesenchymal cells [31, 32]. This gene is
regulated by a number of pathways such asWnt signaling and
bone morphogenetic protein (BMP) signaling [11]. Also,
runx2 participates in the occurrence of many tumors
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[33–38]. In a previous study, Xiaodong et al. proved a higher
expression of runx2 gene and lower expression of sox9 gene
in DDCS cell lines compared with CCS cell lines. However,
what results in the different expression of sox9 and runx2
remains unknown.
Canonical Wnt signaling plays a significant role in
regulating a number of biological processes [10, 13]. Many
researches show that aberrant Wnt signaling participates in
many kinds of diseases such as digestive tract tumors or
osteoporosis [14–18]. TCF-1 is a member of TCF/LEF family,
which is the downstream effector of canonical Wnt signaling.
Although the role of TCF/LEF family has been studied in
many tumors such as gastrointestinal tumor or leukemia, the
role of TCF-1 in dedifferentiated chondrosarcoma was not
explored yet. Day et al. reported that Wnt signaling
determines chondrogenesis or ossification via sox9 and runx2
[11]. Gaur et al. reported that TCF-1 participates in
osteogenesis via runx2 gene as well as Smad1/5 [12].
Miclea et al. found that Wnt/TCF can regulate the expression
of sox9 [39]. This study proposed a novel mechanism that
TCF-1 can regulate runx2 and sox9 in DDCS, and it is closely
related to the patients’ prognosis. Using ChIP and EMSA
technologies, it was found that TCF-1 can upregulate runx2
by binding to its promoter region directly, which is consistent
with other previous studies. However, the ChIP and EMSA
findings showed that TCF-1 could downregulate sox9, but it
could not bind to its promoter region, indicating the existence
of some other molecules that mediate the TCF-1 effect. This
needs further investigation to figure out the specific
mechanism.
Other important pathways that control the bone or cartilage
formation are the BMP/Smad pathway [40, 41] and nonca-
nonical Wnt pathway. The BMP/Smad pathway also partici-
pates in the formation of many tumors [42]. It is reported that
the BMPR2 expression level in DDCS is much higher than
that in CCS, which may have something to do with the DDCS
formation. Jiao et al. showed a higher pathologic grade of
chondrosarcoma and a higher expression level of BMPR2.
Also, its expression level is related to the patients’ prognosis
[43]. The noncanonical Wnt pathway consists of many sub-
families, one of which is the PLC-Ca2+-TAK1-NLK pathway.
Many studies reported that this pathway could repress the
growth of many tumors [44–47]. It is also reported that
nemo-like kinase (NLK), a member of the PLC-Ca2+-TAK1-
NLK cascade, can regulate the canonical Wnt pathway and
BMP/Smad pathway through phosphorylation of TCF-1 pro-
tein as well as Smad protein [10, 48, 49]. It is considered that
DDCS formation may be a cross-talk effect of BMP/Smad
pathway, canonical Wnt pathway, and noncanonical Wnt
pathway. This needs to be investigated further.
In conclusion, this study proved that TCF-1 participates in
the dedifferentiation of DDCS, which may be mediated by
runx2 gene and sox9 gene. The results suggest that TCF-1
can be of important prognostic value. More importantly, it
can be a promising therapeutic target for DDCS patients.
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